Regen BioPharma Inc (RGBP): My guess is that your broker is in the p...

all the way up green · 2024-07-05T17:56:34.4530000Z

My guess is that your broker is in the process of paying out your dividend. My account on the other hand shows nothing, no change at all.

Play Episode

8min

Proactive - Interviews for investors

Sintana Energy advances Orange Basin portfolio with key exploration updates

Sintana Energy CEO Robert Bose recently spoke with Steve Darling from Proactive to provide a comprehensive update on the company’s Orange Basin assets, highlighting significant progress across PEL 83, PEL 90, PEL 87, and PEL 82. Bose sahred positive results from the Mopane 3-X well on PEL 83, operated by Galp. The well, which targeted new AVO anomalies 10 and 13, delivered better-than-expected results across nearly every parameter, confirming the presence of high-quality oil and condensate. This discovery has the potential to establish a new development hub, positioning PEL 83 as a key asset in the basin. Moving forward, activity will focus on evaluating partnership opportunities, with Galp expected to seek new partners in the coming quarters. The first Chevron-operated well on PEL 90 did not encounter commercial hydrocarbons but was still regarded as a technical success. Bose emphasized the company’s confidence in the exploration potential of the block, noting that the joint venture partners plan to return for further drilling later this year. Bose also provided an update on PEL 87’s Saturn Superfan prospect, where Woodside Energy chose not to proceed after completing a 3D seismic survey. Despite this, Sintana remains highly optimistic and is now in discussions with alternative supermajor partners. “We’re very excited about opening up the doors to larger, potential partners,” Bose stated, highlighting the continued confidence in the asset’s potential. Chevron has officially completed its farm-in at PEL 82, located in the Walvis Basin, paving the way for drilling operations next year. Bose also pointed to the growing political support for oil and gas development in Namibia, with upstream regulatory oversight now moved directly under the President’s office—a move he called “a huge step forward” for the industry. This shift reinforces the government’s commitment to fostering a thriving energy sector that could significantly contribute to national GDP growth. #pro

Proactive - Interviews for investors

ACG Metals CFO says hold hedge strategy is already paying off

ACG Metals Ltd chief financial officer Patrick Henze talked with Proactive's Stephen Gunnion about the company’s recently announced gold hedging strategy and its importance during ACG’s transition phase from precious to base metals. Henze explained that while ACG Metals is ultimately targeting copper production from its Gediktepe mine in Turkey by 2026, the mine currently generates strong cash flow from gold and silver. The company has moved to hedge 50% of its gold production at US$2,875 per ounce through January 2026, helping secure revenue in a volatile pricing environment. He noted: “We are currently producing gold and silver, which is a perfect transition for us to become a copper producer in ’26… we can benefit and protect a bit the cash flows by hedging the gold.” The hedge program, executed with Alpha, involves no cash outlay and allows ACG to retain upside exposure above US$3,065 per ounce on the hedged portion. Henze emphasised this strategy helps ACG provide more certainty to bondholders and equity investors by de-risking key financial metrics for 2025. The company remains unhedged on silver and copper, maintaining exposure for future upside. For more updates, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe, and turn on notifications for future content. #ACGMetals #GoldHedging #CopperTransition #GediktepeMine #MiningStrategy #GoldPrices #Commodities #CashFlowManagement #MiningInvestment #ProactiveInvestors

Proactive - Interviews for investors

Nevis Brands doubles revenue in 2024, cuts losses & expands in key Markets

Nevis Brands CEO John Kueber joined Steve Darling from Proactive to discuss the company’s financial results for fiscal year 2024 and the fourth quarter ending November 30, 2024. Nevis reported $1.56 million in revenue, more than doubling its 2023 sales as it expanded into new markets and introduced new cannabis products. The company narrowed its net loss to approximately $362,000, down from $400,000 the previous year. When excluding interest, depreciation, and amortization, the adjusted loss was reduced to about $58,000. Nevis maintained its leading position in Washington’s cannabis beverage market and achieved the second-best sales ranking in Missouri within its first year in that state. The company also made significant progress in debt reduction, cutting current liabilities from $1.12 million to about $573,000 through debt payments and restructuring. Looking ahead to 2025, Nevis expects continued growth driven by expanding sales of its Happy Apple and Major brands in the hemp-derived THC beverage market. The company also looking for market re-entry in Ohio and Arizona following previous licensing and market shifts. All this happening while the company focused on licensing established products in key markets. Kueber acknowledged that the fourth quarter was challenging, with revenue declines due to licensing and market shifts in Arizona, Ohio, Oregon, and California. However, growth in New Jersey and Missouri helped offset these declines, and the company remains focused on long-term expansion and profitability. #proactiveinvestors #nevisbrandsinc #cse #nevi #otcqb #nevif #majorbrand #cannabis #CannabisInvesting #THCDrinks #HappyApple #CannabisStocks #HempTHC #CannabisBeverages #InvestorUpdate #JohnKueber #CannabisNews #CannabisRevenue #DebtReduction #ProactiveInvestors

Proactive - Interviews for investors

Allergy Therapeutics turns the corner, targets market launches

Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) chief executive Manuel Llobet and chief financial officer Shaun Furlong talked with Proactive's Stephen Gunnion about the company’s financial turnaround and ongoing progress across key clinical programs. Allergy Therapeutics reported a return to operating profit before R&D, exceptional and fundraising costs, supported by topline growth and strict cost control. Llobet highlighted that the company saw a 4% constant currency growth in euro-denominated sales—double that of the previous period—driven by improved supply chains and the strong performance of new and registered products. “The top line is good in terms of quantity and quality,” he said. Furlong added that these results, along with the recent financial restructuring, demonstrate a clear path to sustainable health. The company’s cash position rose to £21.7 million at the end of December from £12.9 million in June, aided by external funding and shareholder support. On the clinical side, Llobet described the Grass MATA MPL program as a potential “game changer”, with a Marketing Authorisation Application submitted in Germany. He also noted the progress of the Polyvac Peanut program, which aims to offer a short-course treatment capable of disease modification, differentiating it from current therapies. The company remains focused on progressing these pipeline assets while maintaining financial discipline. For more exclusive interviews, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe, and turn on notifications to stay updated. #AllergyTherapeutics #BiotechNews #Immunotherapy #GrassMATA #PeanutAllergy #VaccineDevelopment #R&D #Pharmaceuticals #FinancialResults #InvestorUpdates #ProactiveInvestors

Followers	15
Posts	748
Boards Moderated	0
Alias Born	01/20/2021

Volume:	5,301
Day Range:	0.05 - 0.0729
Bid:	0.0427
Ask:	0.071
Last Trade Time:	3:17:04 PM EDT
Total Trades:	11

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

RGBP Detailed Quote

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Go Ad-Free